Amgen has opened up on its pricing strategy for its Amjevita (adalimumab-atto) biosimilar, offering further details on why it chose to launch the first US biosimilar at two different price points.
Amgen Talks Dual Pricing Strategy For Amjevita
Debut US Humira Biosimilar Has Been Priced To Address ‘Complexity Of The US Market’
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
